We serve Chemical Name:Methyl 3-methylisonicotinate CAS:116985-92-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Methyl 3-methylisonicotinate
CAS.NO:116985-92-3
Synonyms:methyl 3-methylpyridine-4-carboxylate
Molecular Formula:C8H9NO2
Molecular Weight:151.16300
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:221.1ºC at 760mmHg
Density:1.104g/cm3
Index of Refraction:1.51
PSA:39.19000
Exact Mass:151.06300
LogP:1.17660
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like methyl 3-methylpyridine-4-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 3-methylpyridine-4-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 3-methylpyridine-4-carboxylate Use and application,methyl 3-methylpyridine-4-carboxylate technical grade,usp/ep/jp grade.
Related News: In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being. Methyl 3-methylisonicotinate manufacturer The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. Methyl 3-methylisonicotinate supplier In August, the Company announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,370,452 covering compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell, including an iPSC. Methyl 3-methylisonicotinate vendor The European Medicines Agency did not say how many shots were affected, but Reuters has reported it involves millions of doses, making it harder for J&J to meet a target of delivering 55 million to Europe by end of June. Methyl 3-methylisonicotinate factory In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.
